On January 5, 2026, MetaVia, Inc. (MTVA) announced positive and statistically significant results from the 8-week, non-titrated 48 mg cohort from the Phase 1b trial of DA-1726, the company's dual oxyntomodulin analog that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist. The results from that cohort showed a 9.1% (21.2 lbs) average weight loss through Day 54 along with a statistically significant 9.8 cm reduction in waist circumference (P=0.022). The patients also demonstrated a 12.3 mg/dL improvement in fasting glucose from baseline along with a 23.7% reduction in liver stiffness. The company will next move on to a 16-week titration study, which we anticipate initiating in the first quarter of 2026 with topline results being available in the fourth quarter of 2026.
